UAMY Reports Robust 2025 Growth but Execution Hurdles Loom Large

What happened

United States Antimony Corporation announced fiscal year 2025 revenues of $39.26 million, a 163% year-over-year increase, with gross profit up 185%, driven by higher antimony prices and new contracts totaling $354 million. However, the Defense Logistics Agency indefinite-delivery contract, a key part of this growth, had zero recognized revenue through September 2025, as revenue is gated by shipment acceptance rather than contract awards. The company's expansion at Thompson Falls involves $22.4 million in capex, with $8 million already paid, but operating cash flow remained negative due to working capital builds, including antimony inventory rising to $7.99 million. While management highlights strong demand and pricing, filings indicate growth was price-led rather than volume-driven, exposing the business to commodity volatility and supplier cost pressures. Critical milestones, such as DLA delivery acceptance and commissioning of new capacity, remain unproven, keeping near-term execution risks elevated.

Implication

The strong revenue and profit gains in 2025 are positive but largely reliant on favorable antimony pricing, which may not persist amid market fluctuations. New contracts like the DLA IDIQ offer potential, but zero recognized revenue to date underscores acceptance-gating issues that could delay cash inflows. Negative operating cash flow and inventory buildup signal working capital strain, heightening the risk of further equity dilution beyond the $21.4 million ATM issuance in 2025. Upcoming catalysts, including DLA shipment acceptance and Thompson Falls commissioning by mid-2026, are essential to validate volume-led growth and justify current valuations. Without clear progress on these fronts, the stock remains speculative, with downside amplified by potential dilution and execution missteps.

Thesis delta

The investment thesis remains unchanged: upside depends on converting strategic contracts into delivered-and-accepted shipments without additional dilution, while downside risks persist from operational delays and funding needs. The FY2025 results confirm price-led growth but do not address core concerns over DLA revenue recognition or expansion milestones, reinforcing the need for caution until these are resolved.